Brief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
Mon 18:30
BRIEF-MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety Oct 19 (Reuters) - Maat Pharma SA MAAT.PA:
MAAT PHARMA RECEIVES FDA FEEDBACK FOLLOWING PRE-IND MEETING SUPPORTING CONTINUED DEVELOPMENT OF MAAT034 IN SOLID TUMORS
MAAT PHARMA - PLANS TYPE C FDA MEETING ON MAAT034 CLINICAL DEVELOPMENT
MAAT PHARMA - FDA INDICATES NO ADDITIONAL NONCLINICAL STUDIES REQUIRED FOR MAAT034 SAFETY
MAAT PHARMA - COULD INITIATE MAAT034 FIRST-IN-HUMAN STUDY IN LATE 2027
Source text: ID:nBw2wHSVwa
Further company coverage: MAAT.PA
(Reporting by Zakia Mariyam)
((Zakia.Mariyam@thomsonreuters.com;))
Recent news on Maat Pharma SA
See all newsBrief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026